Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration

The pharmacokinetics and pharmacodynamics of warfarin remained unaffected by tolvaptan during clinical trials. However, tolvaptan prolonged the prothrombin time–international normalized ratio (PT–INR) level of patients with cardiovascular disease taking warfarin. Tolvaptan was prescribed to 576 pati...

Full description

Saved in:
Bibliographic Details
Published in:Biological & pharmaceutical bulletin 2018/07/01, Vol.41(7), pp.1014-1016
Main Authors: Saito, Masayuki, Ajioka, Masayoshi, Iwao, Takahiro, Suzuki, Tadashi
Format: Article
Language:English
Subjects:
Anticoagulants
Cardiovascular diseases
Clinical trials
phamacodynamics
pharmacist
Pharmacodynamics
Pharmacokinetics
Prothrombin
tolvaptan
Variation
Warfarin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c444t-553fbc943ea1b9716c08bbcacf8d5d12484d6cdc901af3eb276bc7676e2c32c23
cites cdi_FETCH-LOGICAL-c444t-553fbc943ea1b9716c08bbcacf8d5d12484d6cdc901af3eb276bc7676e2c32c23
container_end_page 1016
container_issue 7
container_start_page 1014
container_title Biological & pharmaceutical bulletin
container_volume 41
creator Saito, Masayuki
Ajioka, Masayoshi
Iwao, Takahiro
Suzuki, Tadashi
description The pharmacokinetics and pharmacodynamics of warfarin remained unaffected by tolvaptan during clinical trials. However, tolvaptan prolonged the prothrombin time–international normalized ratio (PT–INR) level of patients with cardiovascular disease taking warfarin. Tolvaptan was prescribed to 576 patients from December 2010 to December 2015. Of these patients, 37 underwent anticoagulant therapy. We investigated PT–INR fluctuation immediately before tolvaptan therapy was initiated. PT–INR remained unchanged in the control group and in groups administered with less than 7.5 mg/d tolvaptan, whereas it was significantly increased (p=0.03) in the group administered with more than 7.5 mg/d tolvaptan. This result indicates the possibility that tolvaptan affects the pharmacodynamics of warfarin in vivo. However, further research is necessary to clarify the mechanism of this phenomenon.
doi_str_mv 10.1248/bpb.b17-01008
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2039296533</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2039296533</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-553fbc943ea1b9716c08bbcacf8d5d12484d6cdc901af3eb276bc7676e2c32c23</originalsourceid><addsrcrecordid>eNpdkc1v1DAQxS0EokvhyBVF4sIlxZ9xcqxWpUWqVISKOFpjZ9L1KnGC7RTx3-Ptlj0gWePD-83TzDxC3jN6wbhsP9vFXlima8oobV-QDRNS14oz9ZJsaMfaumGqPSNvUtpTSjXl4jU5451uqKBqQ4arsIPgcMKQq3mofkIcIPpQXYbs3QwP6whF-Y7gsp9DVZRvkH2hU_Xb511RFoSMfXUXYazu5_ERlgylv5988ClHOPS9Ja8GGBO-e_7PyY8vV_fbm_r27vrr9vK2dlLKXCslBus6KRCY7TRrHG2tdeCGtlf9YV_ZN653HWUwCLRcN9bpRjfIneCOi3Py6ei7xPnXiimbySeHY1kC5zUZTkXHu0YJUdCP_6H7eY2hTGc4l-UpLrtC1UfKxTmliINZop8g_jGMmsNApgRgSgDmKYDCf3h2Xe2E_Yn-d_ECbI_APmV4wBMAsdx7xCc7yYw-lJPtSXU7iAaD-AvDHJo6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242245249</pqid></control><display><type>article</type><title>Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration</title><source>Free Full-Text Journals in Chemistry</source><creator>Saito, Masayuki ; Ajioka, Masayoshi ; Iwao, Takahiro ; Suzuki, Tadashi</creator><creatorcontrib>Saito, Masayuki ; Ajioka, Masayoshi ; Iwao, Takahiro ; Suzuki, Tadashi</creatorcontrib><description>The pharmacokinetics and pharmacodynamics of warfarin remained unaffected by tolvaptan during clinical trials. However, tolvaptan prolonged the prothrombin time–international normalized ratio (PT–INR) level of patients with cardiovascular disease taking warfarin. Tolvaptan was prescribed to 576 patients from December 2010 to December 2015. Of these patients, 37 underwent anticoagulant therapy. We investigated PT–INR fluctuation immediately before tolvaptan therapy was initiated. PT–INR remained unchanged in the control group and in groups administered with less than 7.5 mg/d tolvaptan, whereas it was significantly increased (p=0.03) in the group administered with more than 7.5 mg/d tolvaptan. This result indicates the possibility that tolvaptan affects the pharmacodynamics of warfarin in vivo. However, further research is necessary to clarify the mechanism of this phenomenon.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b17-01008</identifier><identifier>PMID: 29760305</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Anticoagulants ; Cardiovascular diseases ; Clinical trials ; phamacodynamics ; pharmacist ; Pharmacodynamics ; Pharmacokinetics ; Prothrombin ; tolvaptan ; Variation ; Warfarin</subject><ispartof>Biological and Pharmaceutical Bulletin, 2018/07/01, Vol.41(7), pp.1014-1016</ispartof><rights>2018 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-553fbc943ea1b9716c08bbcacf8d5d12484d6cdc901af3eb276bc7676e2c32c23</citedby><cites>FETCH-LOGICAL-c444t-553fbc943ea1b9716c08bbcacf8d5d12484d6cdc901af3eb276bc7676e2c32c23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29760305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Saito, Masayuki</creatorcontrib><creatorcontrib>Ajioka, Masayoshi</creatorcontrib><creatorcontrib>Iwao, Takahiro</creatorcontrib><creatorcontrib>Suzuki, Tadashi</creatorcontrib><title>Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration</title><title>Biological &amp; pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>The pharmacokinetics and pharmacodynamics of warfarin remained unaffected by tolvaptan during clinical trials. However, tolvaptan prolonged the prothrombin time–international normalized ratio (PT–INR) level of patients with cardiovascular disease taking warfarin. Tolvaptan was prescribed to 576 patients from December 2010 to December 2015. Of these patients, 37 underwent anticoagulant therapy. We investigated PT–INR fluctuation immediately before tolvaptan therapy was initiated. PT–INR remained unchanged in the control group and in groups administered with less than 7.5 mg/d tolvaptan, whereas it was significantly increased (p=0.03) in the group administered with more than 7.5 mg/d tolvaptan. This result indicates the possibility that tolvaptan affects the pharmacodynamics of warfarin in vivo. However, further research is necessary to clarify the mechanism of this phenomenon.</description><subject>Anticoagulants</subject><subject>Cardiovascular diseases</subject><subject>Clinical trials</subject><subject>phamacodynamics</subject><subject>pharmacist</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Prothrombin</subject><subject>tolvaptan</subject><subject>Variation</subject><subject>Warfarin</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdkc1v1DAQxS0EokvhyBVF4sIlxZ9xcqxWpUWqVISKOFpjZ9L1KnGC7RTx3-Ptlj0gWePD-83TzDxC3jN6wbhsP9vFXlima8oobV-QDRNS14oz9ZJsaMfaumGqPSNvUtpTSjXl4jU5451uqKBqQ4arsIPgcMKQq3mofkIcIPpQXYbs3QwP6whF-Y7gsp9DVZRvkH2hU_Xb511RFoSMfXUXYazu5_ERlgylv5988ClHOPS9Ja8GGBO-e_7PyY8vV_fbm_r27vrr9vK2dlLKXCslBus6KRCY7TRrHG2tdeCGtlf9YV_ZN653HWUwCLRcN9bpRjfIneCOi3Py6ei7xPnXiimbySeHY1kC5zUZTkXHu0YJUdCP_6H7eY2hTGc4l-UpLrtC1UfKxTmliINZop8g_jGMmsNApgRgSgDmKYDCf3h2Xe2E_Yn-d_ECbI_APmV4wBMAsdx7xCc7yYw-lJPtSXU7iAaD-AvDHJo6</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Saito, Masayuki</creator><creator>Ajioka, Masayoshi</creator><creator>Iwao, Takahiro</creator><creator>Suzuki, Tadashi</creator><general>The Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20180701</creationdate><title>Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration</title><author>Saito, Masayuki ; Ajioka, Masayoshi ; Iwao, Takahiro ; Suzuki, Tadashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-553fbc943ea1b9716c08bbcacf8d5d12484d6cdc901af3eb276bc7676e2c32c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anticoagulants</topic><topic>Cardiovascular diseases</topic><topic>Clinical trials</topic><topic>phamacodynamics</topic><topic>pharmacist</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Prothrombin</topic><topic>tolvaptan</topic><topic>Variation</topic><topic>Warfarin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saito, Masayuki</creatorcontrib><creatorcontrib>Ajioka, Masayoshi</creatorcontrib><creatorcontrib>Iwao, Takahiro</creatorcontrib><creatorcontrib>Suzuki, Tadashi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological &amp; pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saito, Masayuki</au><au>Ajioka, Masayoshi</au><au>Iwao, Takahiro</au><au>Suzuki, Tadashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration</atitle><jtitle>Biological &amp; pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>41</volume><issue>7</issue><spage>1014</spage><epage>1016</epage><pages>1014-1016</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>The pharmacokinetics and pharmacodynamics of warfarin remained unaffected by tolvaptan during clinical trials. However, tolvaptan prolonged the prothrombin time–international normalized ratio (PT–INR) level of patients with cardiovascular disease taking warfarin. Tolvaptan was prescribed to 576 patients from December 2010 to December 2015. Of these patients, 37 underwent anticoagulant therapy. We investigated PT–INR fluctuation immediately before tolvaptan therapy was initiated. PT–INR remained unchanged in the control group and in groups administered with less than 7.5 mg/d tolvaptan, whereas it was significantly increased (p=0.03) in the group administered with more than 7.5 mg/d tolvaptan. This result indicates the possibility that tolvaptan affects the pharmacodynamics of warfarin in vivo. However, further research is necessary to clarify the mechanism of this phenomenon.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>29760305</pmid><doi>10.1248/bpb.b17-01008</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0918-6158
ispartof Biological and Pharmaceutical Bulletin, 2018/07/01, Vol.41(7), pp.1014-1016
issn 0918-6158
1347-5215
language eng
recordid cdi_proquest_miscellaneous_2039296533
source Free Full-Text Journals in Chemistry
subjects Anticoagulants
Cardiovascular diseases
Clinical trials
phamacodynamics
pharmacist
Pharmacodynamics
Pharmacokinetics
Prothrombin
tolvaptan
Variation
Warfarin
title Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T21%3A58%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhancement%20of%20Warfarin%20Anticoagulant%20Reaction%20in%20Patients%20with%20Repeated%20Oral%20Tolvaptan%20Administration&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Saito,%20Masayuki&rft.date=2018-07-01&rft.volume=41&rft.issue=7&rft.spage=1014&rft.epage=1016&rft.pages=1014-1016&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b17-01008&rft_dat=%3Cproquest_cross%3E2039296533%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c444t-553fbc943ea1b9716c08bbcacf8d5d12484d6cdc901af3eb276bc7676e2c32c23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2242245249&rft_id=info:pmid/29760305&rfr_iscdi=true